Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01741194 · ClinicalTrials.gov registry record · Phase 2
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A Phase 2 study, sponsored by Cerecin.
- Completed
- Registry status
- Phase 2
- Development phase
- 418
- Enrollment target
NCT01741194: Completed Phase 2 study, sponsored by Cerecin.
NCT01741194 is a Phase 2 study that has completed, run by Cerecin. The registered enrollment target is 418 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (214% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01741194, a Phase 2 study, has completed, sponsored by Cerecin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 418 participants
- Enrollment target
Study Summary
This study will evaluate the effects of daily dosing of AC-1204 on cognition, activities of daily living, resource utilization, quality of life, pharmacokinetic measures and safety among participants with mild to moderate Alzheimer's Disease.
Primary Outcome
APOE(-) participants
Interventions
- DRUG Placebo
- DRUG AC-1204
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 418 participants |
| Start Date | 2013-03 |
| Est. Completion | 2017-04-14 |
| Phase | Phase 2 |
What the finished NCT01741194 record still lists
NCT01741194 is an interventional study that assigns participants to a tested intervention. The registered 418 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (214% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01741194 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01741194 about?
NCT01741194 is a clinical study titled "AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext". This study will evaluate the effects of daily dosing of AC-1204 on cognition, activities of daily living, resource utilization, quality of life, pharmacokinetic measures and safety among participants with mild to moderate Alzheimer's Disease.
What is the current status of trial NCT01741194?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 418 participants. The study started on 2013-03. Estimated completion is 2017-04-14.
What interventions are being tested in trial NCT01741194?
The interventions under investigation include: Placebo (DRUG), AC-1204 (DRUG).
Who is sponsoring clinical trial NCT01741194?
This trial is sponsored by Cerecin, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01741194's enrollment target sits among peer trials
418 91st of 2000 higher than 1,910 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03135886 · 418 participants · NA
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
- NCT05579639 · 419 participants · Phase 2
Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant
- NCT06169735 · 417 participants · Phase 4
Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation
- NCT06699901 · 417 participants
Antibiotic Concentrations After MassivE Transfusion Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia